Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
医学
来曲唑
癌症
肿瘤科
乳腺癌
内科学
妇科
作者
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon-Sim Yap,Gabe S. Sonke,Lowell Hart,Mario Campone,Katarina Petrakova,Eric P. Winer,Wolfgang Janni,Pierfranco Conte,David A. Cameron,Fabrice André,Carlos L. Arteaga,Juan P. Zarate,Arunava Chakravartty,Tetiana Taran,Fabienne Le Gac,Paolo Serra,Joyce O’Shaughnessy
First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo. (Funded by Novartis; MONALEESA-2 ClinicalTrials.gov number, NCT01958021.).
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
大力的灵雁
识字岭的岭
Twonej
tiptip
8R60d8
pluto
蓝莓橘子酱
dew
科研狗
916
挖掘机
Singularity
BowieHuang
菠菜
乐空思
Sea_U
HH
Lylin
风吹麦田
皖公网安备34019202002308
